HALEOS LABS LIMITED (HALEOSLABS) — Board Meeting | 29 May 2026

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

The board approved audited FY2026 financial results with a ₹1.501/share dividend (subject to shareholder approval), confirmed an unmodified audit opinion, reappointed Sudeepthi Gopineedi as Whole-time Director for 5 years (shareholder approval pending), and disclosed related party transactions and new auditor appointments. The filing also detailed cash flow positions and compliance with new labour codes.

📄 View Original Announcement (PDF)

About HALEOS LABS LIMITED (HALEOSLABS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹460.98 Cr P/E: 29.2 ROE: 7.8% ROCE: 10.0% Div Yield: 0.10%

View full HALEOSLABS stock details →

📡 Get AI alerts when HALEOSLABS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track HALEOSLABS — Free

📊 More HALEOSLABS filings

See all HALEOSLABS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when HALEOSLABS files new disclosures

Track HALEOSLABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track HALEOSLABS — Free

Free account · 2 AI queries/day